2018
Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis
Khera R, Pandey A, Chandar AK, Murad MH, Prokop LJ, Neeland IJ, Berry JD, Camilleri M, Singh S. Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis. Gastroenterology 2018, 154: 1309-1319.e7. PMID: 29305933, PMCID: PMC5880739, DOI: 10.1053/j.gastro.2017.12.024.Peer-Reviewed Original ResearchConceptsWeight loss medicationsCardiometabolic risk profileHigh-density lipoprotein cholesterolWaist circumferenceDrug AdministrationSystematic reviewRisk profileLipoprotein cholesterolHemoglobin A1cObese adultsCholesterol profileSystolic/diastolic BPCardiometabolic risk factorsNetwork Meta-AnalysisRandomized clinical trialsQuality of evidenceLow-density lipoproteinModest decreaseOutcomes of interestEffect of foodLong-term useMinimal effectLiraglutide useOrlistat useBlood pressure
2016
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA 2016, 315: 2424-2434. PMID: 27299618, PMCID: PMC5617638, DOI: 10.1001/jama.2016.7602.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdverse eventsClinical trialsWeight lossObese adultsHigher oddsAdverse event-related treatment discontinuationSystematic reviewSignificant excess weight lossCumulative ranking (SUCRA) probabilitiesDiscontinuation of therapyExcess weight lossProportion of patientsManagement of obesityQuality of evidenceWeight loss agentsWeb of ScienceTreatment discontinuationCochrane CENTRALPharmacological treatmentMagnitude of decreaseGRADE criteriaDrug treatmentLiraglutideMAIN OUTCOMEPlacebo participants